Aprogen Biologics Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Jeong-Chool Kim

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

We Wouldn't Rely On Aprogen pharmaceuticalsInc's (KRX:003060) Statutory Earnings As A Guide

Jan 16

Aprogen pharmaceuticals,Inc.'s (KRX:003060) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Dec 20

Is Aprogen pharmaceuticalsInc (KRX:003060) A Risky Investment?

Nov 24

CEO

Jeong-Chool Kim

no data

Permanencia

Jeong-Chool Kim serves as the Chief Operating Officer of Aprogen, Inc. Jeong Chul Kim serves as Chief Executive Officer of Gen-Exel Medical Inc. and Aprogen pharmaceuticals,Inc. (formerly known as Schnell...

Aprogen Biologics Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Aprogen pharmaceuticals,Inc., Annual General Meeting, Mar 29, 2021

Recent updates

New major risk - Revenue and earnings growth

Full year 2023 earnings released: ₩187 loss per share (vs ₩31.00 profit in FY 2022)

New minor risk - Market cap size

New minor risk - Share price stability

Third quarter 2023 earnings released: ₩7.00 loss per share (vs ₩11.00 profit in 3Q 2022)

Investor sentiment improves as stock rises 66%

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

First quarter 2023 earnings released: EPS: ₩2.00 (vs ₩7.00 in 1Q 2022)

Full year 2022 earnings released: EPS: ₩19.00 (vs ₩20.00 in FY 2021)

Investor sentiment improves as stock rises 16%

Now 21% undervalued after recent price drop

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: EPS ₩7.00 (vs ₩12.00 in 3Q 2020)

First quarter 2021 earnings released: EPS ₩5.00 (vs ₩16.00 in 1Q 2020)

Aprogen pharmaceuticals,Inc., Annual General Meeting, Mar 29, 2021

New 90-day low: ₩1,235

We Wouldn't Rely On Aprogen pharmaceuticalsInc's (KRX:003060) Statutory Earnings As A Guide

Aprogen pharmaceuticals,Inc.'s (KRX:003060) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Is Aprogen pharmaceuticalsInc (KRX:003060) A Risky Investment?

New 90-day low: ₩1,300

Aprogen pharmaceuticals,Inc. has completed a Follow-on Equity Offering in the amount of KRW 235.376127 billion.

CEO

Permanencia